For patients with metastatic uveal melanoma, what are the treatment options? Marlana M. Orloff, M.D.: Metastatic uveal melanoma is unique in that when patients recur, close to 90% or more recur in ...

What advice do you have for patients and caregivers of those recently diagnosed with uveal melanoma? Marlana M. Orloff, M.D.: Because metastatic uveal melanoma is so rare, it’s very important that ...

LUND, SE / ACCESS Newswire / October 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and ...

Credit: Shutterstock. Hepzato Kit is supplied with the Hepzato 5x5 Drug Pack and the HDS; it is expected to be available in the fourth quarter of 2023. The Food and Drug Administration (FDA) has ...

Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French ...

Hepzato Kit, FDA-approved for metastatic uveal melanoma liver treatment, shows strong early revenue ($10M in Q3, $13.7M expected in Q4) with surprising profitability. The disease affects ~1,700 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

Relationship between socio-economic status and education grade on Breslow thickness and ulceration in clinical stage I-II AJCC skin melanoma: Analysis from a single institution prospectively collected ...

MADRID — The positive effect of the bispecific fusion protein tebentafusp on the overall survival of patients with uveal melanoma in the IMCgp100-202 study lasted through at least 36 months of ...

RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with previously treated disease WOBURN, Mass., Nov.

Discover why Ideaya Biosciences, Inc. is rated a Buy for its promising oncology pipeline and upcoming catalysts. Click for my ...